What is an additional year of healthy human life worth?
What is an additional year of healthy human life worth?
The question sounds philosophical. It is increasingly economic.
Economists have long understood education as an investment in human capital: expenditure today that can increase productive capacity tomorrow. We have been less precise about health. Healthcare still appears predominantly in public debate as a cost, something governments,insurers and households must finance, rather than as an asset capable of producing an economic return.
That distinction is becoming harder to sustain.
By 2050, the global population aged 60 and above is expected to reach 2.1 billion. The IMF estimates that healthier aging could add around 0.4 percentage points to annual global GDP growth between 2025 and 2050. Behind those numbers sits a larger structural question: as populations live longer, can economies extend productive life at something approaching the same rate?
This is why the distinction between lifespan and healthspan matters.
An economy gains relatively little from adding years to life if those years are accompanied by rising dependency, chronic illness and escalating healthcare costs. Extend the period in which people remain healthy, independent and economically active, however, and longevity begins to look less like a fiscal liability and more like an economic asset.
Seen through that lens, the UAE’s investment in longevity is particularly significant.
Health as human capital
GCC healthcare expenditure is forecast to reach $159 billion by 2029, while more than 160 healthcare projects worth approximately $53.2 billion are currently underway across the region. Dubai alone recorded AED24.55 billion in healthcare expenditure in 2024, an increase of 10 percent in a year. Private financing accounted for 62 percent of that expenditure.
The question, therefore, is no longer whether capital will flow into healthcare. It is what kind of healthcare economy that capital will create.
A healthier population can participate productively in an economy for longer. Earlier diagnosis can reduce expensive late-stage interventions. Prevention can reduce the long-term burden of chronic disease on governments, insurers, employers and families. Health, viewed this way, is a stock of human capital. Poor health depreciates it. Prevention preserves it. Innovation can extend its productive life.
That shifts healthcare from being simply a question of expenditure towards something more interesting: investment in productive capacity.
The UAE is building a market, not simply participating in one
This is where the UAE’s approach deserves attention.
Dubai established the Dubai Longevity Authority this year with a mandate spanning research and development, clinical studies, advanced therapeutics, investment, technology transfer and the development of a regulated longevity market. Abu Dhabi’s Health, Endurance, Longevity and Medicine (HELM) cluster takes a similarly integrated approach, connecting biotechnology, pharmaceuticals, MedTech, genomics and artificial intelligence with investment and commercialization.
The economic ambition is substantial. By 2045, HELM is projected to contribute more than AED94 billion to Abu Dhabi’s GDP, attract over AED42 billion in investment and create approximately 30,000 jobs.
Commercial momentum is becoming visible too. Last week, DUPHAT concluded in Dubai with approximately AED10.3 billion in direct and indirect pharmaceutical trade deals.
Taken separately, these are healthcare developments. Taken together, they begin to look like industrial strategy.
That distinction matters.
One of the UAE’s particular economic strengths has been its ability to construct ecosystems around sectors it considers strategically important: institutions, regulation, infrastructure, capital and talent. We saw this with aviation and logistics, followed by financial services and renewable energy. We are watching it again with artificial intelligence and advanced technology. Healthcare and longevity are a natural extension of that model.
There is also an important advantage in timing. Several advanced economies are confronting longevity through shrinking workforces, rising dependency ratios and growing pension and healthcare liabilities. The UAE is investing in healthspan before aging becomes a fiscal constraint primarily.
In policy terms, that is a considerably stronger position from which to allocate capital.
Financing the longevity dividend
There is an important complication, however. Markets do not necessarily allocate capital according to where economic value is greatest. They allocate it towards where returns can most readily be captured.
That distinction is particularly acute in healthcare.
A new therapy or diagnostic platform has a customer, a price and, eventually, a revenue model. Prevention is economically messier.
Preventing diabetes may create value for decades through lower healthcare expenditure, reduced absenteeism, higher productivity and improved quality of life. Yet no single actor captures all of that value. The return is distributed between individuals, employers, insurers, families and the state.
The result is a familiar economic problem: the social return on prevention can exceed its privately investable return.
This is where impact investment becomes more than an adjunct to the longevity conversation. Properly structured, it can help correct the mismatch between who finances an intervention and who ultimately benefits from it.
Blended finance can bring public, philanthropic and private capital together where risks and returns are unevenly distributed. Outcomes-based structures can link returns to measurable improvements in health, while catalytic capital can help innovations bridge the difficult journey from clinical validation to commercial scale.
This is not about attaching an impact label to every healthcare asset. The discipline lies in distinguishing between an investment that happens to sit within healthcare and one capable of generating measurable additional economic and social value.
The UAE is particularly well equipped for this next phase. The foundations are already in place: capital, regulatory agility, scientific capability, sophisticated healthcare infrastructure and the capacity to convene government, researchers and private investors around long-term objectives.
The global longevity race will not be determined simply by who develops the next breakthrough therapy. The larger economic prize lies in the ecosystem around it: where research is financed, intellectual property is created, companies are scaled and talent chooses to locate.
Many economies begin confronting the economics of longevity only when aging becomes a fiscal constraint.
The UAE is investing while it remains an opportunity. That is not simply healthcare policy. It is anticipatory economic policy. And perhaps that is the longevity dividend that matters most: not the pursuit of living indefinitely, but investment in the productive potential of human life.
For the UAE, health is increasingly becoming part of the infrastructure of the future.
Source: economymiddleeast